Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Neuromuscular disorders : NMD - 1 Dec 2010

Forrest Sarah, Meloni Penny L, Muntoni Francesco, Kim Jihee, Fletcher Sue, Wilton Steve D

Abstract excerpt

Antisense oligomer induced exon skipping is showing promise as a therapy to reduce the severity of Duchenne muscular dystrophy. To date, the focus has been on excluding single exons flanking frame-shifting deletions in the dystrophin gene. However, a third of all Duchenne muscular dystrophy causi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dystrophin
Share to Exons
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscular Dystrophy, Duchenne

Share to Mutation

Share to Myoblasts

Share to Oligonucleotides, Antisense

Share to Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 20817455
DOI: 10.1016/j.nmd.2010.07.276
PMCID: PMC2991584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20817455-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.PMID 20817455Read ↗

Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.Semantic proximity Read ↗

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and ChallengesSemantic proximity Read ↗

Exon skipping: a first in class strategy for Duchenne muscular dystrophySemantic proximity Read ↗

Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?Semantic proximity Read ↗

Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide ApproachSemantic proximity Read ↗

Rapid and scalable preclinical evaluation of personalized antisense oligonucleotide therapeutics using organoids derived from rare disease patientsSemantic proximity Read ↗

Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.Semantic proximity Read ↗

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.Semantic proximity Read ↗

Translational development of splice-modifying antisense oligomersSemantic proximity Read ↗

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular DystrophySemantic proximity Read ↗

Redirecting splicing to address dystrophin mutations: molecular by-pass surgery.Semantic proximity Read ↗

Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.